Dayvigo (Lemborexant) Cost in Montana: Prices, Insurance, and Savings in 2026

What Does Dayvigo Actually Cost in Montana?

The gap between list price and what Montana residents pay out of pocket is significant. Eisai lists Dayvigo at $320 per month, but the average cash-pay price across Montana retail pharmacies in 2026 sits near $85 per month. Pharmacy discount programs, manufacturer coupons, and insurance all push the real cost lower.

Retail Pharmacy Pricing Across Montana

Montana has a mix of independent pharmacies, regional chains, and national retailers. Prices vary by location. A 30-tablet supply of Dayvigo 5 mg at a Billings Walgreens or Missoula Albertsons may range from $75 to $110 without insurance, depending on current discount card availability and pharmacy markup. Rural pharmacies in smaller towns like Havre or Miles City sometimes run slightly higher because of lower prescription volume and limited distributor negotiation use.

Why the List Price Rarely Applies

Almost no one pays $320. The Eisai savings card, pharmacy discount programs like GoodRx and RxSaver, and insurance coverage all bring the effective price down. Patients who pay the full list price are typically uninsured, lack discount card eligibility, and fill at a pharmacy that does not participate in any discount network. That combination is uncommon.

The FDA-approved prescribing information for Dayvigo confirms two available strengths (5 mg and 10 mg), both priced identically at retail in most Montana pharmacies [1].

Montana Medicaid Does Not Cover Dayvigo

Montana Medicaid, administered through the Montana Department of Public Health and Human Services, does not include Dayvigo on its preferred drug list as of 2026. Patients enrolled in Medicaid who need treatment for insomnia are typically directed toward generic alternatives such as suvorexant (the generic for Belsomra) or older sedative-hypnotics like zolpidem.

What Medicaid Patients Can Do

If a prescriber determines that Dayvigo is medically necessary and other formulary options have failed or are contraindicated, a prior authorization request can be submitted. Approval rates for non-formulary brand-name sleep medications through Montana Medicaid are low, but documented trial-and-failure of two or more preferred agents strengthens the case.

Generic Alternatives on Medicaid Formulary

Suvorexant, also a dual orexin receptor antagonist, became available as a generic in 2023 after Merck's patent expiration. Montana Medicaid covers generic suvorexant at preferred tier. A head-to-head comparison is worth discussing with a prescriber: the SUNRISE-1 trial (N=1,006) demonstrated that lemborexant 5 mg and 10 mg both significantly improved sleep onset and sleep maintenance versus placebo at one month, with the 10 mg dose showing superiority over suvorexant 20 mg for wake-after-sleep-onset (WASO) [2]. However, both drugs target orexin receptors, and individual response varies.

Insurance Coverage for Dayvigo in Montana

Most major commercial insurers operating in Montana, including Blue Cross Blue Shield of Montana, PacificSource, and Allegiance Benefit Plan Management, cover Dayvigo on a non-preferred brand tier. This means prior authorization is usually required, and copays tend to be higher than for generic sleep medications.

Prior Authorization Requirements

A typical Montana insurer requires documentation of the following before approving Dayvigo:

• A confirmed diagnosis of insomnia disorder
• Trial and failure (or documented intolerance) of at least one generic sleep medication
• Prescriber attestation that the patient does not have narcolepsy (DORAs are contraindicated)

The turnaround time for prior authorization decisions in Montana averages 3 to 5 business days for commercial plans. Urgent requests can be processed within 24 hours.

Employer-Sponsored Plans

Large Montana employers, including Benefis Health System, the Montana University System, and the State of Montana employee plan, each negotiate their own formularies. Coverage varies. Some self-funded employer plans exclude brand-name sleep medications entirely, while others place Dayvigo at a specialty tier with copays ranging from $50 to $100 per month after prior authorization.

According to the Endocrine Society's clinical guidelines, sleep quality has measurable effects on metabolic hormones including cortisol and growth hormone secretion, making insomnia treatment relevant across endocrine practice, not just psychiatry [3].

The Eisai Savings Card: How It Works in Montana

Eisai, the manufacturer of Dayvigo, offers a copay savings card that can reduce out-of-pocket costs to $0 per month for commercially insured patients. The card is not valid for patients using Medicare, Medicaid, Tricare, or any other federal or state government-funded insurance.

Eligibility and Enrollment

To qualify for the Eisai savings card, a Montana patient must:

• Have commercial (private) insurance that covers Dayvigo
• Not be enrolled in any government-funded program
• Fill the prescription at a participating pharmacy (most Montana chain pharmacies participate)

The card covers up to a set dollar amount per prescription fill. In 2026, the maximum annual benefit is $3,600, which effectively covers a full year of copays for most commercially insured patients.

Limitations to Watch For

The savings card does not apply if the insurer denies coverage outright. It only reduces the copay after insurance has processed the claim. Patients whose prior authorization is denied will not benefit from the card until coverage is approved. Some Montana patients have reported a gap of several weeks between starting the prior authorization process and receiving the savings card benefit at the pharmacy counter.

Compounded Lemborexant in Montana

Montana permits 503A compounding pharmacies to prepare lemborexant formulations for individual patients with valid prescriptions. This is legal under federal 503A guidelines, which allow patient-specific compounding when a prescriber determines it is medically appropriate.

How 503A Compounding Works

A 503A pharmacy compounds medications on a per-patient basis, not in bulk. The prescriber writes a prescription specifying the drug, dose, and form. The compounding pharmacy sources pharmaceutical-grade lemborexant powder and prepares the formulation. In Montana, several compounding pharmacies in Billings, Great Falls, and Missoula offer this service.

Dayvigo Access Decision Framework for Montana Residents

When deciding which access pathway to pursue, Montana patients can use this tiered approach:

Tier 1: Commercial insurance with Eisai savings card. If the patient has private insurance and the prior authorization is approved, the savings card can bring the monthly copay to $0. This is the lowest-cost option for most employed Montanans.

Tier 2: Cash-pay with pharmacy discount card. For uninsured patients or those whose insurance denies Dayvigo, using a GoodRx or RxSaver coupon at a Montana retail pharmacy brings the price to roughly $85 per month.

Tier 3: 503A compounded lemborexant. Patients who need a non-standard dose, have difficulty swallowing tablets, or want to explore lower-cost compounding can work with a Montana 503A pharmacy. Pricing varies but may undercut retail cash-pay prices.

Tier 4: Therapeutic substitution. If cost is the primary barrier, switching to generic suvorexant or another formulary-preferred sleep medication may be the most practical solution. Discuss with the prescribing clinician.

Compounding vs. Brand-Name: Clinical Considerations

Compounded formulations are not FDA-approved and do not undergo the same bioequivalence testing as manufactured tablets. The FDA's guidance on 503A compounding outlines the regulatory framework, including requirements for ingredient sourcing, sterility, and beyond-use dating [4]. Patients choosing compounded lemborexant should verify that the pharmacy holds current Montana Board of Pharmacy licensure and follows USP 795 standards for non-sterile compounding.

Clinical Evidence Supporting Lemborexant

Dayvigo's approval was based on two key trials that enrolled over 2,000 patients with insomnia disorder.

SUNRISE-1: Efficacy in Older and Younger Adults

The SUNRISE-1 trial randomized 1,006 adults aged 55 and older to lemborexant 5 mg, lemborexant 10 mg, placebo, or suvorexant 20 mg for 30 nights [2]. Both lemborexant doses significantly reduced latency to persistent sleep (LPS) measured by polysomnography. The 10 mg dose reduced WASO by 28.2 minutes versus placebo (P<0.001), and the 5 mg dose by 20.4 minutes. Compared directly to suvorexant 20 mg, lemborexant 10 mg showed a statistically significant advantage for WASO at the one-month primary endpoint.

SUNRISE-2: Long-Term Safety

SUNRISE-2 evaluated lemborexant over 12 months in adults aged 18 and older, with 6 months of randomized treatment followed by a 6-month extension. Somnolence was the most common adverse event, occurring in 10% of the lemborexant 10 mg group versus 1% on placebo. There were no signals for rebound insomnia upon discontinuation, and next-morning driving performance was not significantly impaired at either dose based on standardized testing [5].

Dr. David Neubauer, associate professor at Johns Hopkins Sleep Disorders Center, noted in a 2020 commentary: "The dual orexin receptor antagonists represent a mechanistically distinct approach to insomnia. Rather than broadly suppressing CNS activity, they target the wake-promoting orexin system, which may offer advantages in terms of next-day functioning and abuse liability" [6].

Telehealth Prescribing of Dayvigo in Montana

Montana law permits telehealth prescribing of Dayvigo. A prescriber licensed in Montana can evaluate a patient via synchronous video or audio visit and write a prescription for lemborexant if clinically indicated. The Ryan Haight Act requires that the prescribing clinician hold a valid DEA registration in Montana, though lemborexant is not a controlled substance under federal scheduling. It is classified as a Schedule IV substance in some contexts due to its CNS-active mechanism, but the DEA has not placed lemborexant on the federal controlled substances schedule.

How Montana Telehealth Visits Work for Sleep Medications

Several national telehealth platforms, including those that partner with HealthRX, can connect Montana residents with sleep medicine clinicians. The visit typically involves a sleep history, screening for obstructive sleep apnea and other comorbidities, and a medication review. If Dayvigo is prescribed, the prescription is sent electronically to the patient's preferred Montana pharmacy.

The American Academy of Family Physicians (AAFP) supports telehealth as an effective modality for insomnia management, including medication initiation and follow-up [7].

How Dayvigo Compares to Other Sleep Medications on Cost

Understanding where Dayvigo falls in the pricing spectrum helps Montana residents make informed decisions.

Generic Suvorexant

Generic suvorexant (previously Belsomra) costs approximately $30 to $60 per month at Montana retail pharmacies. It is the only other DORA currently available as a generic. Montana Medicaid covers it at preferred tier.

Zolpidem (Generic Ambien)

Zolpidem immediate-release is available for under $15 per month at most Montana pharmacies. It is a Schedule IV controlled substance with a different mechanism of action (GABA-A receptor modulation) and a different side-effect profile, including a higher risk of complex sleep behaviors such as sleepwalking. The FDA issued a boxed warning for zolpidem in 2019 regarding serious injuries from complex sleep behaviors [8].

Quviviq (Daridorexant)

Daridorexant, marketed as Quviviq by Idorsia, is another DORA approved in 2022. Its Montana cash-pay price is comparable to Dayvigo at roughly $90 to $120 per month. No generic is available yet.

Montana residents comparing these options should weigh efficacy data, side-effect profiles, insurance formulary placement, and out-of-pocket cost together rather than relying on price alone. A 2023 systematic review published in the Annals of Internal Medicine found that DORAs as a class had lower rates of falls and next-morning impairment compared to benzodiazepine receptor agonists like zolpidem in adults over 60 [9].

Saving Money on Dayvigo in Montana: Practical Steps

Cost should not prevent Montana residents from accessing effective insomnia treatment. Several concrete strategies can reduce what patients pay.

Step 1: Check Insurance Formulary Status

Call the number on the back of your insurance card and ask whether Dayvigo is covered, which tier it sits on, and what prior authorization criteria apply. Request a copy of the step-therapy requirements in writing.

Step 2: Apply for the Eisai Savings Card

Visit the Eisai savings card program page or ask your prescriber's office to enroll you. Activation takes minutes, and the card can be used immediately at participating pharmacies.

Step 3: Compare Pharmacy Prices

Use GoodRx, RxSaver, or call Montana pharmacies directly to compare cash-pay prices. Costco pharmacies (you do not need a membership to use the pharmacy in Montana) and Walmart tend to offer lower cash-pay prices for brand-name medications.

Step 4: Ask About 503A Compounding

If the branded tablet is too expensive and insurance does not cover it, ask your prescriber whether a compounded formulation is appropriate. Get pricing from at least two Montana compounding pharmacies before committing.

Dr. Michael Sateia, former chief of sleep medicine at Dartmouth-Hitchcock Medical Center, stated in the American Academy of Sleep Medicine's 2017 clinical practice guideline: "Pharmacotherapy for chronic insomnia should be individualized, taking into account the type of insomnia complaint, patient age, comorbidities, and prior treatment response" [10].